Lantheus Holdings (NASDAQ: LNTH) held its fourth-quarter and full-year 2024 earnings call on Feb. 26, 2025, highlighting achievements in its radiopharmaceutical portfolio and announcing strategic ...

Q4 2024 Earnings Call Transcript February 26, 2025 Operator: Good morning. Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being ...

Welcome to the Lantheus Fourth Quarter and Full Year 2024 Conference Call. [Operator Instructions]. This call is being recorded and a replay will be available in the Investors section of the company's ...

Worldwide revenue of $391.1 million and $1.53 billion for the fourth quarter and full year 2024Free cash flow was $141.4 million and $493.1 ...

We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

In the fourth quarter of 2024, the US Gross Domestic Product (GDP) expanded at an annual rate of 2.3%, slightly below market ...

LNTH READ THE FULL LNTH RESEARCH REPORT Lantheus Holdings, Inc. (NASDAQ:LNTH) began 2025 with a pair of potentially ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics. Lantheus ...

Lantheus, a Massachusetts-based developer of radiopharmaceuticals, has agreed to acquire the radiopharma contract development and manufacturing organization (CDMO) Evergreen Theragnostics.

“With Evergreen's manufacturing and development capabilities, we become fully integrated. We are pleased to welcome Evergreen's talented team to Lantheus and are confident that their expertise in ...